Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.

Yusuke Miyazaki,Masashi Funada,Shingo Nakayamada,Koshiro Sonomoto,Hiroaki Tanaka,Kentaro Hanami,Shunsuke Fukuyo,Satoshi Kubo,Ayako Yamaguchi,Ippei Miyagawa,Yasuyuki Todoroki,Masanobu Ueno,Yoshiya Tanaka

Rheumatology (Oxford, England)（2023）

引用 0|浏览3

暂无评分

摘要

At week 26 after initiating anifrolumab therapy, ∼90% patients remained on therapy. Anifrolumab might lower disease activity without initiating GCs and reduce GC doses, especially in patients who experience minor flares after LLDAS achievement.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要